Breast Cancer Research

Table 2 Prognostic value of HER2 status (HER2-low vs. HER2-0)

From: Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)

		5-year survival	Unadjusted HR (CI)	Adjusted HR (CI)^a
IDFS	HER2-0	82.1%	0.92 (0.80 – 1.05)	0.93 (0.81 – 1.06)
IDFS	HER2-low	83.5%	0.92 (0.80 – 1.05)	0.93 (0.81 – 1.06)
DRFS	HER2-0	85.5%	0.94 (0.81 – 1.10)	0.96 (0.82 – 1.12)
DRFS	HER2-low	86.5%	0.94 (0.81 – 1.10)	0.96 (0.82 – 1.12)
OS	HER2-0	92.5%	0.94 (0.76 – 1.16)	0.96 (0.78 – 1.18)
OS	HER2-low	92.9%	0.94 (0.76 – 1.16)	0.96 (0.78 – 1.18)

HR hazard ratio, CI confidence interval, IDFS invasive disease-free survival, DRFS distant relapse-free survival, OS overall survival. ^aAdjusted for age, T-stage, N-stage, grade, and progesterone receptor status

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com